Tamoxifen
- Generic Name
- Tamoxifen
- Brand Names
- Soltamox
- Drug Type
- Small Molecule
- Chemical Formula
- C26H29NO
- CAS Number
- 10540-29-1
- Unique Ingredient Identifier
- 094ZI81Y45
- Background
Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations. Tamoxifen is used alone or as an adjuvant in these treatments. Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, s...
- Indication
Tamoxifen is indicated to treat estrogen receptor positive metastatic breast cancer in adults, as an adjuvant in the treatment of early stage estrogen receptor positive breast cancer in adults, to reduce the risk of invasive breast cancer after surgery and radiation in adult women with ductal carcinoma in situ.
- Associated Conditions
- Breast Cancer, Contralateral Breast Cancer, Desmoid Tumor, Early Stage Estrogen Receptor (ER) Positive Breast Cancer, Gynecomastia, Invasive Breast Cancer, Ovarian Cancer, Puberty, Precocious, Metastatic Estrogen Receptor Positive Breast Cancer
- Associated Therapies
- Ovulation induction therapy
Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression
- Conditions
- Interventions
- First Posted Date
- 2019-03-12
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- AC Camargo Cancer Center
- Target Recruit Count
- 23
- Registration Number
- NCT03870399
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
🇧🇷AC Camargo Cancer Center, São Paulo, SP, Brazil
Analgesic Efficacy of Pulsed Radiofrequency in Non-cyclic Mastalgia
- Conditions
- Interventions
- First Posted Date
- 2018-10-23
- Last Posted Date
- 2019-03-07
- Lead Sponsor
- Mansoura University
- Target Recruit Count
- 64
- Registration Number
- NCT03715413
- Locations
- 🇪🇬
Yahay wahba, Mansourah, Egypt
Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis
- Conditions
- Interventions
- First Posted Date
- 2018-10-01
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Emory University
- Target Recruit Count
- 38
- Registration Number
- NCT03691493
- Locations
- 🇺🇸
Grady Health System, Atlanta, Georgia, United States
🇺🇸Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
🇺🇸Lewis Cancer and Research Pavilion at Saint Joseph's/Candler, Savannah, Georgia, United States
T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Invasive Breast CarcinomaAnatomic Stage IV Breast Cancer AJCC v8HER2/Neu NegativeAnatomic Stage IIIC Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIC Breast Cancer AJCC v8Prognostic Stage III Breast Cancer AJCC v8Prognostic Stage IV Breast Cancer AJCC v8
- Interventions
- First Posted Date
- 2018-06-12
- Last Posted Date
- 2023-05-15
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 20
- Registration Number
- NCT03554044
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension
- First Posted Date
- 2018-05-18
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 18
- Registration Number
- NCT03528902
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY
- Conditions
- Interventions
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- National Cancer Center, Japan
- Target Recruit Count
- 180
- Registration Number
- NCT03423199
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇨🇳Sun Yat-Sen Cancer Center, Taipei, Taiwan
🇯🇵Chiba Cancer Center, Chiba, Japan
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2017-12-26
- Last Posted Date
- 2024-07-03
- Target Recruit Count
- 31
- Registration Number
- NCT03382834
- Locations
- 🇺🇸
Penn Therapeutics, CRS, Philadelphia, Pennsylvania, United States
🇺🇸Massachusetts General Hospital CRS (MGH CRS), Boston, Massachusetts, United States
🇺🇸Cincinnati Clinical Research Site, Cincinnati, Ohio, United States
Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer
- First Posted Date
- 2017-12-14
- Last Posted Date
- 2017-12-18
- Lead Sponsor
- Zhiyong Yu
- Target Recruit Count
- 200
- Registration Number
- NCT03373708
Tamoxifen in Duchenne Muscular Dystrophy
- Conditions
- Interventions
- First Posted Date
- 2017-11-27
- Last Posted Date
- 2022-12-20
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 93
- Registration Number
- NCT03354039
- Locations
- 🇪🇸
Hospital Sant Joan de Déu. UB, Esplugues de Llobregat, Barcelona, Spain
🇨🇭University Children's Hospital Basel, Basel, Switzerland
🇫🇷Hôpital de Hautepierre, Strasbourg, France
Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer
- First Posted Date
- 2017-11-22
- Last Posted Date
- 2017-11-22
- Lead Sponsor
- Chinese Anti-Cancer Association
- Target Recruit Count
- 844
- Registration Number
- NCT03351062
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Hebei Tumor Hospital, Shijiazhuang, Hebei, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.